Sapphire Energy Inc

www.sapphireenergy.com

San Diego-based Sapphire Energy is pioneering an approach that takes two very old processes and synthesizes them into one very new opportunity. Farming and algae have been around for most of human existence, but the two have not been paired in any significant way to bring leverage the positive effects on one another.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

NEXEO PLASTICS AND EARTH RENEWABLE TECHNOLOGIES SIGN AGREEMENT TO DISTRIBUTE BIOCOMPOUNDS IN NORTH AMERICA

Nexeo Plastics | March 02, 2022

news image

Nexeo Plastics, a leading global thermoplastics resin distributor, has announced an agreement with Earth Renewable Technologies, Inc. (ERT), a biotechnology company, to distribute ERT’s BioCompounds in Canada and the United States. “We are extremely pleased to collaborate with ERT to increase the slate of sustainable products we offer our customers. ERT’s BioCompounds complement the products we already carry and help us close the gap in our ...

Read More

STEMCYTE SUBMITTED ITS APPLICATION FOR A BIOLOGICS LICENSE (BLA) FOR ITS PRODUCT "HPC-CORD BLOOD" TO THE US FDA

Stemcyte | March 23, 2022

news image

On January 7th, 2022, the FDA received the BLA (Biologics License Application) for the "HPC-Cord Blood" product. On March 8th, 2022, StemCyte was formally informed that the submission was acceptable to join the biologics license quality review process. The "HPC-Cord Blood" is an umbilical cord blood hematopoietic stem cell product intended for unrelated donor hematopoietic progenitor cell transplantation procedures in patients with hematopoietic system disorder...

Read More

AXIM® BIOTECHNOLOGIES COMPLETES PRE-CLINICAL DRUG STUDIES ON NEW COMPOUND PROVING TENFOLD GREATER INHIBITION OF TUMOR METASTASIS THAN PARENT COMPOUND

BioSpace | March 24, 2020

news image

Axim Biotech® Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that its subsidiary Sapphire Biotech, Inc. (“Sapphire”) has completed pre-clinical drug studies on a new compound, SPX-1009, demonstrating 10 times greater potency than its parent compound, SBI-183, in inhibiting metastasis....

Read More

Cell and Gene Therapy

NEUROPHTH AND AAVNERGENE ANNOUNCES STRATEGIC AAV CAPSIDS PARTNERSHIP FOR NEXT-GENERATION OPHTHALMIC GENE THERAPY

Neurophth | January 19, 2021

news image

Neurophth Therapeutics, Inc., a subsidiary of Wuhan Neurophth Biotechnology Ltd. gene therapy organization, and AAVnerGene Inc., a practicing AAV innovation organization, reports a strategic partnership to provide Neurophth with overall rights to commonly choose adeno-associated virus (AAV) capsids for the next generation ophthalmic gene therapy. AAVnerGene's Tissue-specific, Highly-transductive and Expressive New AAVs (ATHENA) screening stage can productively choose the best ...

Read More
news image

Industrial Impact

NEXEO PLASTICS AND EARTH RENEWABLE TECHNOLOGIES SIGN AGREEMENT TO DISTRIBUTE BIOCOMPOUNDS IN NORTH AMERICA

Nexeo Plastics | March 02, 2022

Nexeo Plastics, a leading global thermoplastics resin distributor, has announced an agreement with Earth Renewable Technologies, Inc. (ERT), a biotechnology company, to distribute ERT’s BioCompounds in Canada and the United States. “We are extremely pleased to collaborate with ERT to increase the slate of sustainable products we offer our customers. ERT’s BioCompounds complement the products we already carry and help us close the gap in our ...

Read More
news image

STEMCYTE SUBMITTED ITS APPLICATION FOR A BIOLOGICS LICENSE (BLA) FOR ITS PRODUCT "HPC-CORD BLOOD" TO THE US FDA

Stemcyte | March 23, 2022

On January 7th, 2022, the FDA received the BLA (Biologics License Application) for the "HPC-Cord Blood" product. On March 8th, 2022, StemCyte was formally informed that the submission was acceptable to join the biologics license quality review process. The "HPC-Cord Blood" is an umbilical cord blood hematopoietic stem cell product intended for unrelated donor hematopoietic progenitor cell transplantation procedures in patients with hematopoietic system disorder...

Read More
news image

AXIM® BIOTECHNOLOGIES COMPLETES PRE-CLINICAL DRUG STUDIES ON NEW COMPOUND PROVING TENFOLD GREATER INHIBITION OF TUMOR METASTASIS THAN PARENT COMPOUND

BioSpace | March 24, 2020

Axim Biotech® Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that its subsidiary Sapphire Biotech, Inc. (“Sapphire”) has completed pre-clinical drug studies on a new compound, SPX-1009, demonstrating 10 times greater potency than its parent compound, SBI-183, in inhibiting metastasis....

Read More
news image

Cell and Gene Therapy

NEUROPHTH AND AAVNERGENE ANNOUNCES STRATEGIC AAV CAPSIDS PARTNERSHIP FOR NEXT-GENERATION OPHTHALMIC GENE THERAPY

Neurophth | January 19, 2021

Neurophth Therapeutics, Inc., a subsidiary of Wuhan Neurophth Biotechnology Ltd. gene therapy organization, and AAVnerGene Inc., a practicing AAV innovation organization, reports a strategic partnership to provide Neurophth with overall rights to commonly choose adeno-associated virus (AAV) capsids for the next generation ophthalmic gene therapy. AAVnerGene's Tissue-specific, Highly-transductive and Expressive New AAVs (ATHENA) screening stage can productively choose the best ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us